Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23794996 | 0.82 | SLC6A4 (0.41) | NR3C1 | |
| SCHEMBL2366778 | 0.82 | SLC6A4 (0.41) | NR3C1 | |
| SCHEMBL16335384 | 0.82 | SLC6A4 (0.41) | NR3C1 | |
| SCHEMBL2367386 | 0.79 | CYP3A4 (0.46) | SMN1; SMN2 | |
| SCHEMBL25890502 | 0.79 | NPC1 (0.43) | NR3C1SMN1; SMN2 | |
| SCHEMBL24105665 | 0.78 | NR3C1 (0.32) | NR3C1 | |
| SCHEMBL25890544 | 0.78 | NR3C1 (0.32) | NR3C1 | |
| SCHEMBL25890550 | 0.76 | GLP1R (0.32) | — | |
| SCHEMBL25890554 | 0.76 | GLP1R (0.32) | — | |
| SCHEMBL25890496 | 0.74 | CYP3A4 (0.43) | NR3C1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640497-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20180368410-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-12-27 | — | — | US | disclosed |
| US-20180362515-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| US-20180265483-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PATRICIPATIONS AG (CH) | 2018-09-20 | — | — | US | disclosed |
| EP-2364293-B1 | NOVEL PYRAZOLE-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-8258169-B2 | Pyrazole-4-N-alkoxycarboxamides as microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110230537-A1 | NOVEL PYRAZOLE-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION LLC (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2364293-A2 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010063700-A2 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230537-A1 | NOVEL PYRAZOLE-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES | CASP1, CASP14, CD14 | NR3C1 3314/4885ABCB1 1487/4885SMN1; SMN2 3572/4885 |
| US-10640497-B2 | Microbiocidal oxadiazole derivatives | PRF1, ARG1, ARG2 | NR3C1 2026/4885ABCB1 1159/4885SMN1; SMN2 2882/4885 |
| US-20180265483-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX3, ARG2 | NR3C1 1961/4885ABCB1 1162/4885SMN1; SMN2 2902/4885 |
| US-20180362515-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, ARG1, ARG2 | NR3C1 2026/4885ABCB1 1159/4885SMN1; SMN2 2882/4885 |
| US-20180368410-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | NR3C1 1617/4885ABCB1 1049/4885SMN1; SMN2 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.